Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334840 | 0.84 | DRD2 (0.45) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6635893 | 0.84 | DRD2 (0.45) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6343665 | 0.82 | DRD2 (0.46) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL2702516 | 0.82 | DRD2 (0.46) | SIGMAR1DRD2DRD3DRD4MTNR1A | |
| SCHEMBL5216890 | 0.79 | DRD2 (0.49) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL5216589 | 0.79 | DRD2 (0.49) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6345240 | 0.74 | CA1 (0.43) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6335390 | 0.74 | CA1 (0.43) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6619572 | 0.73 | DRD2 (0.43) | SIGMAR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6334436 | 0.72 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD3HTR1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010123995-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | SIGMAR1 181/4885DRD2 2/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.